Ken Fisher's NVO Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 10.3M shares of Novo Nordisk A/S (NVO) worth $572.82 M, representing 0.21% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in NVO, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2017, adding 2.7M shares. Largest reduction occurred in Q3 2022, reducing 10.0M shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Ken Fisher
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +26.91 M | Add 0.00% | 26.91 M | $15.50 |
| Q3 2013 | +115,500 | Add 0.43% | 27.03 M | $16.92 |
| Q4 2013 | +56,260 | Add 0.21% | 27.08 M | $18.48 |
| Q1 2014 | +179,288 | Add 0.66% | 27.26 M | $22.83 |
| Q2 2014 | +219,100 | Add 0.80% | 27.48 M | $23.09 |
| Q3 2014 | -711,232 | Reduce 2.59% | 26.77 M | $23.81 |
| Q4 2014 | -692,530 | Reduce 2.59% | 26.08 M | $21.16 |
| Q1 2015 | -758,826 | Reduce 2.91% | 25.32 M | $26.70 |
| Q2 2015 | -728,742 | Reduce 2.88% | 24.59 M | $27.38 |
| Q3 2015 | -1.29 M | Reduce 5.23% | 23.3 M | $27.12 |
| Q4 2015 | -409,710 | Reduce 1.76% | 22.89 M | $29.04 |
| Q1 2016 | -537,208 | Reduce 2.35% | 22.36 M | $28.07 |
| Q2 2016 | -431,430 | Reduce 1.93% | 21.93 M | $27.68 |
| Q3 2016 | -104,850 | Reduce 0.48% | 21.82 M | $20.80 |
| Q4 2016 | -578,262 | Reduce 2.65% | 21.24 M | $17.93 |
| Q1 2017 | -525,066 | Reduce 2.47% | 20.72 M | $17.14 |
| Q2 2017 | +2.66 M | Add 12.86% | 23.38 M | $21.45 |
| Q3 2017 | +867,454 | Add 3.71% | 24.25 M | $24.08 |
| Q4 2017 | +1.16 M | Add 4.79% | 25.41 M | $26.84 |
| Q1 2018 | +848,360 | Add 3.34% | 26.26 M | $24.63 |
| Q2 2018 | +880,028 | Add 3.35% | 27.14 M | $23.06 |
| Q3 2018 | +455,466 | Add 1.68% | 27.59 M | $23.57 |
| Q4 2018 | +811,062 | Add 2.94% | 28.41 M | $23.03 |
| Q1 2019 | +753,474 | Add 2.65% | 29.16 M | $26.16 |
| Q2 2019 | +643,124 | Add 2.21% | 29.8 M | $25.52 |
| Q3 2019 | +620,132 | Add 2.08% | 30.42 M | $25.85 |
| Q4 2019 | -246,216 | Reduce 0.81% | 30.18 M | $28.94 |
| Q1 2020 | +473,726 | Add 1.57% | 30.65 M | $30.10 |
| Q2 2020 | +315,554 | Add 1.03% | 30.97 M | $32.74 |
| Q3 2020 | +440,988 | Add 1.42% | 31.41 M | $34.72 |
| Q4 2020 | +251,048 | Add 0.80% | 31.66 M | $34.92 |
| Q1 2021 | +451,690 | Add 1.43% | 32.11 M | $33.71 |
| Q2 2021 | +54,584 | Add 0.17% | 32.16 M | $41.88 |
| Q3 2021 | +187,104 | Add 0.58% | 32.35 M | $48.01 |
| Q4 2021 | -473,216 | Reduce 1.46% | 31.88 M | $56.00 |
| Q1 2022 | -55,658 | Reduce 0.17% | 31.82 M | $55.53 |
| Q2 2022 | -3.18 M | Reduce 10.00% | 28.64 M | $55.72 |
| Q3 2022 | -9.97 M | Reduce 34.82% | 18.67 M | $49.81 |
| Q4 2022 | -613,722 | Reduce 3.29% | 18.05 M | $67.67 |
| Q1 2023 | -2.3 M | Reduce 12.75% | 15.75 M | $79.57 |
| Q2 2023 | -510,072 | Reduce 3.24% | 15.24 M | $80.92 |
| Q3 2023 | -491,657 | Reduce 3.23% | 14.75 M | $90.94 |
| Q4 2023 | -618,485 | Reduce 4.19% | 14.13 M | $103.45 |
| Q1 2024 | -404,880 | Reduce 2.87% | 13.72 M | $128.40 |
| Q2 2024 | -354,091 | Reduce 2.58% | 13.37 M | $142.74 |
| Q3 2024 | -65,153 | Reduce 0.49% | 13.31 M | $119.07 |
| Q4 2024 | -664,985 | Reduce 5.00% | 12.64 M | $86.02 |
| Q1 2025 | -769,253 | Reduce 6.09% | 11.87 M | $69.44 |
| Q2 2025 | -870,320 | Reduce 7.33% | 11 M | $69.02 |
| Q3 2025 | -678,013 | Reduce 6.16% | 10.32 M | $55.49 |
Ken Fisher's Novo Nordisk A/S Investment FAQs
Ken Fisher first purchased Novo Nordisk A/S (NVO) in Q2 2013, acquiring 26,912,910 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Novo Nordisk A/S (NVO) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher's largest addition to Novo Nordisk A/S (NVO) was in Q2 2013, adding 26,912,910 shares worth $417.07 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 10,322,903 shares of Novo Nordisk A/S (NVO), valued at approximately $572.82 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.21% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher's peak holding in Novo Nordisk A/S (NVO) was 32,351,078 shares, as reported at the end of Q3 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.